

COPY OF PAPERS  
ORIGINALLY FILED

FEB 15 2002

RECEIPT

PTO/SB/21 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL  
FORM

(to be used for all correspondence after initial filing)

TECH CENTER 1600  
290

MAR 05 2002

RECEIVED

Total Number of Pages in This Submission

5

Application Number

09/955,444

Filing Date

09/17/2001

First Named Inventor

James M. Wilson et al

Group Art Unit

1645

Examiner Name

UPN-N2605

## ENCLOSURES (check all that apply)

Fee Transmittal Form  
 Fee Attached

Amendment / Reply  
 After Final  
 Affidavits/declaration(s)

Extension of Time Request

Express Abandonment Request

Information Disclosure Statement

Certified Copy of Priority Document(s)

Response to Missing Parts/ Incomplete Application

Response to Missing Parts under 37 CFR 1.52 or 1.53


Assignment Papers (for an Application)  
 Drawing(s)  
 Licensing-related Papers  
 Petition  
 Petition to Convert to a Provisional Application  
 Power of Attorney, Revocation  
 Change of Correspondence Address  
 Terminal Disclaimer  
 Request for Refund  
 CD, Number of CD(s) \_\_\_\_\_

After Allowance Communication to Group  
 Appeal Communication to Board of Appeals and Interferences  
 Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)  
 Proprietary Information  
 Status Letter  
 Other Enclosure(s) (please identify below):

**Request for  
Correction of Filing  
Receipt w/Exhibits**

Remarks

## SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT


Firm or Individual name	Cathy A. Kodroff, Esquire Howson and Howson	
Signature		
Date	11/19/01	

## CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231 on this date: 11/19/2001

Typed or printed name	Debra N. Gerstemeier		
Signature		Date	11-19-2001

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



COPY OF PAPERS  
ORIGINALLY FILED

UPN-N2605

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of ) Group Art Unit: 1645  
James M. Wilson et al )  
Appln. No. 09/955,444 )  
Filed: September 17, 2001 )  
For: COMPOSITIONS AND METHODS ) November 19, 2001  
USEFUL FOR NON-INVASIVE )  
DELIVERY OF THERAPEUTIC )  
MOLECULES TO THE BLOODSTREAM )

Assistant Commissioner for Patents  
Washington, DC 20231

**REQUEST FOR CORRECTION OF FILING RECEIPT**

Sir:

Enclosed is a copy of the Filing Receipt received in the above-identified patent application. An error in the title of the application has been noted and correction to same is marked in red on the attached copy of the Filing Receipt (Exhibit A). A copy of the first page of the application is attached (Exhibit B) to show the correct title.

Applicants respectfully request that the official filing receipt for this application be corrected to reflect the correct title of the application.

CERTIFICATE UNDER 37 CFR §1.8(a)

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: the Assistant Commissioner for Patents, Washington, DC 20231 on November 19, 2001.

Signature 

Typed or printed name Debra N. Gerstemeier

TECH CENTER 1600/2900  
MAR 05 2002

RECEIVED

The Director of the U. S. Patent and Trademark Office is hereby authorized to charge any deficiency in any fees due with the filing of this paper or credit any overpayment in any fees paid on the filing, or during prosecution of this application to Deposit Account No. 08-3040.

Respectfully submitted,

HOWSON AND HOWSON  
Attorneys for the Applicants

By Cathy A Kodroff  
Cathy A Kodroff  
Registration No. 33,980  
Spring House Corporate Center  
Box 457  
Spring House, PA 19477  
Telephone: (215) 540-9210  
Telefacsimile: (215) 540-5818



FEB 15 2002

## UNITED STATES PATENT AND TRADEMARK OFFICE

 COMMISSIONER FOR PATENTS  
 UNITED STATES PATENT AND TRADEMARK OFFICE  
 WASHINGTON, D.C. 20231  
 www.uspto.gov

APPLICATION NUMBER	FILING DATE	GRP ART UNIT	FIL FEE REC'D	ATTY.DOCKET NO	DRAWINGS	TOT CLAIMS	IND CLAIMS
09/955,444	09/17/2001	1645	746	UPN-N2605	1	22	2

## CONFIRMATION NO. 1285

00270  
 HOWSON AND HOWSON  
 ONE SPRING HOUSE CORPORATION CENTER  
 BOX 457  
 321 NORRISTOWN ROAD  
 SPRING HOUSE, PA 19477

## FILING RECEIPT



\*OC00000007018541\*

RECEIVED

MAR 05 2002

TECH CENTER 1600/2900

Date Mailed: 11/05/2001

Receipt is acknowledged of this nonprovisional Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Customer Service Center. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

## Applicant(s)

James M. Wilson, Gladwyne, PA;  
 Alberto Auricchio, Philadelphia, PA;  
 Markus Hildinger, Evanston, IL;

## Domestic Priority data as claimed by applicant

THIS APPLICATION IS A CIP OF PCT/US01/13000 04/23/2001  
 WHICH CLAIMS BENEFIT OF 60/200,409 04/28/2000

## Foreign Applications

If Required, Foreign Filing License Granted 11/02/2001

Projected Publication Date: To Be Determined - pending completion of Missing Parts

Non-Publication Request: No

Early Publication Request: No

## Title


Compositions and methods useful for non-invasive delivery of therapeutic molecules to the bloodstream

therapeutic

Exh.57 A

Preliminary Class

435

COPY OF PAPERS  
ORIGINALLY FILED

RECEIVED

MAR 05 2002

**LICENSE FOR FOREIGN FILING UNDER  
Title 35, United States Code, Section 184  
Title 37, Code of Federal Regulations, 5.11 & 5.15**

TECH CENTER 1600/2900

**GRANTED**

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

**NOT GRANTED**

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).

RECEIVED

MAR 05 2002

TECH CENTER 1600/2900



COPY OF PAPERS  
ORIGINALLY FILED

UPN-N2605

COMPOSITIONS AND METHODS USEFUL FOR NON-INVASIVE  
DELIVERY OF THERAPEUTIC MOLECULES TO THE BLOODSTREAM

This work was funded, in part, by a grant from the National Institutes of  
5 Health (NIH) P30 DK47757-07 and P01 HL59407-02. The US government has  
certain rights in this invention.

Cross-Reference to Related Applications

This is a continuation-in-part of International Patent Application No.  
PCT/US01/13000, filed April 23, 2001, which claims the benefit of US Patent  
10 Application No. 60/200,409, filed April 28, 2000, which are incorporated by reference  
herein.

Background of the Invention

The invention relates generally to the field of viral vectors useful in gene  
delivery.

15 There are a variety of therapeutic and immunogenic molecules for which  
delivery to the blood is desirable. Such molecules include those useful for treatment  
of blood disorders, e.g., hemophilia, and molecules useful for cancer therapies,  
conferring passive immunity, and a variety of other purposes. However, current  
methods for delivery of such molecules to the blood via viral vectors involve  
20 injection, or other highly invasive methods, which require delivery by health care  
professionals.

What is needed in the art are novel methods for delivering therapeutic and  
immunogenic molecules to the blood.

Express Mail No. ET033435760US

Exhibit B